Anticoagulant Therapy for Acute Venous Thromboembolism: What We Think We Know and What the Data Show for the Timing of Recurrent Events

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 6, 2009, Pages 609-612

  Stein, Paul D ^a   Hull, Russell D ^b   Matta, Fadi ^a   Yaekoub, Abdo Y ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c ST JOSEPH MERCY OAKLAND HOSPITAL   (United States)

Author keywords

deep venous thrombosis; heparin; pulmonary embolism; venous thromboembolism; warfarin

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ACUTE DISEASE; HUMAN; RECURRENT DISEASE; REVIEW; TIME; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; HEPARIN; HUMANS; RECURRENCE; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 75549090097     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609349500     Document Type: Article

References (17)

1. Brandjes DP, Heijboer H., Büller HR, de Rijk M., Jagt H., ten Cate JW Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. NEJM. 1992; 327(21):1485-1489.
2. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997; 157(22):2562-2568. 3.
3. Prandoni P., Carnovali M., Marchiori A. Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med. 2004; 164(10):1077-1083.
4. Basu D., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. NEJM. 1972; 287(7): 324-327.
5. Douketis JD, Kearon C., Bates S., Duku EK, Ginsberg JS Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998; 279(6):458-462.
6. Wessler S., Morris LE Studies in intravascular coagulation IV. The effect of heparin and dicumarol on serum-induced venous thrombosis. Circulation. 1955; 12(4): 553-556.
7. Carey LC, Williams RD Comparative effects of dicoumarol, tromexan, and heparin on thrombus propagation. Ann Surg. 1960; 152(5):919-922.
8. Nicholls SC, O'Brian JK, Sutton MG Venous thromboembolism: detection by duplex scanning. J Vasc Surg. 1996; 23(3):511-516.
9. Murray G., MacKenzie H. Postoperative thrombosis and embolism. Am J Surg. 1942; 57(3):414-428.
10. Filshie I., Scott GB The organisation of experimental venous thrombi. J Pathol Bacteriol. 1958; 76(1):71-76.
11. Marin HM, Stefanini M. Experimental production of phlebothrombosis. Surg Gynecol Obstet. 1960; 110(3): 263-268.
12. Wessler S., Gitel SN Warfarin from bedside to bench. NEJM. 1984;311(10):645-652.
13. Zivelin A., Rao LV, Rapaport SI Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest. 1993; 92(5): 2131-2140.
14. Harrison L., Johnston M., Massicotte MP, Crowther M., Moffat K., Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997; 126(2):133-136.
15. White RH, Zhou H., Romano PS Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med. 1998; 158(9):1005-1010.
16. Anand S., Ginsberg JS, Kearon C., Gent M., Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996; 156(15):1677-1681.
17. Weitz JI, Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990; 86(2):385-391.